SRP3068

IGF-Binding Protein-5 human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

• Synonym(e): IBP-5
• NACRES: NA.32
• UNSPSC Code: 51111800
• Form: lyophilized
• Assay: ≥98% (HPLC), ≥98% (SDS-PAGE)
• Biological source: human
• Recombinant: expressed in E. coli
• Mol wt: 28.6 kDa

Eigenschaften

• biological source: human
• recombinant: expressed in E. coli
• assay: ≥98% (HPLC), ≥98% (SDS-PAGE)
• form: lyophilized
• potency: ≤0.3 μg/mL
• mol wt: 28.6 kDa
• packaging: pkg of 25 μg
• technique(s): cell culture | mammalian: suitable
• impurities: <0.1 EU/μg endotoxin, tested
• color: white to off-white
• UniProt accession no.: P24593
• shipped in: wet ice
• storage temp.: −20°C
• Gene Information: human ... IGFBP5(3488)

Beschreibung

General description

IGFBP5 (insulin-like growth factor-binding protein 5) belongs to the IGFBP family of proteins. IGFBPs are mainly required to regulate IGFs (insulin like growth factors) activities. The gene IGFBP5 is mapped to human chromosome 2q35.
Recombinant human IGF-BP5 is a 28.6kDa protein consisting of 253 amino acid residues.

Biochem/physiol Actions

IGFBP5 (insulin-like growth factor-binding protein 5) works via IGF (insulin like growth factor)-dependent and -independent mechanisms. It can function as a tumor suppressor as well as an oncogene. Changes in the activity of this gene are often observed in human cancers and metastatic tissues. During cancer development, IGFBP5 is involved in cell growth, migration and invasion. IGFBP5 is associated with breast cancer, osteosarcoma, head and neck squamous cell carcinoma, neuroblastoma, prostate cancer and malignant melanoma. It is upregulated in systemic sclerosis and idiopathic pulmonary fibrosis. In primary fibroblasts, IGFBP5 exhibits pro-fibrotic effects. It is strongly expressed in bones and is involved in osteogenic differentiation. Under in vitro conditions, IGFBP5 and its microRNA (microRNA-143-3p) are involved in muscle regeneration.

Physical form

Lyophilized from 10 mM Sodium Citrate, pH 3.0.

Preparation Note

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Other Notes

MLGSFVHCEP CDEKALSMCP PSPLGCELVK EPGCGCCMTC ALAEGQSCGV YTERCAQGLR CLPRQDEEKP LHALLHGRGV CLNEKSYREQ VKIERDSREH EEPTTSEMAE ETYSPKIFRP KHTRISELKA EAVKKDRRKK LTQSKFVGGA ENTAHPRIIS APEMRQESEQ GPCRRHMEAS LQELKASPRM VPRAVYLPNC DRKGFYKRKQ CKPSRGRKRG ICWCVDKYGM KLPGMEYVDG DFQCHTFDSS NVS

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable